Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Jun 27, 2025--
Mr. Brent H. Zettl (the ' acquiror '), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation (' ZYUS ') provides updates to his holdings of Common shares (' Common Shares ') in the capital of ZYUS, Common Share purchase warrants of ZYUS (' Warrants ') and options to purchase Common Shares (' Options ').
On June 27, 2025, the acquiror participated in a non-brokered private placement of units (' Units ') of ZYUS (the ' Private Placement ') at a price of $0.67 per Unit, with each Unit comprised of one Common Share and one half of one Warrant (each whole Warrant, a ' Private Placement Warrant '). Each Private Placement Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, subject to certain acceleration provisions. The acquiror acquired, indirectly through 1189115 B.C. LTD. 298,507 Units (comprised of 298,507 Common Shares and 149,253 Warrants) under the Private Placement.
Immediately prior to the Private Placement, the acquiror owned, directly and indirectly, and exercised control over 33,730,573 Common Shares and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis (assuming full exercise of all of the convertible securities held by the acquiror). Immediately following the Private Placement and as at the date hereof, the acquiror owns, directly and indirectly, and exercises control over 34,029,080 Common Shares, 149,253 Warrants and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Following the Private Placement, the acquiror's securityholding percentage has decreased by 1.4% on an undiluted basis from the percentage held immediately following the September 2024 Event (as defined below) and by 5.4% on an undiluted basis from the percentage disclosed in the last early warning report filed by the acquiror on June 13, 2023 (the ' 2023 EWR '), and has decreased by 1.6% on a partially diluted basis from the acquiror's securityholding percentage held immediately following the September 2024 Event and by 6.1% on a partially diluted basis from the acquiror's securityholding percentage as at June 13, 2023. The acquiror's securityholding percentage on a partially diluted basis as disclosed in the 2023 EWR (51.68%) was stated in error. The correct securityholding percentage on a partially diluted basis as at June 13, 2023 was 50.5%.
Since the completion of the acquisition of ZYUS Life Sciences Inc. by ZYUS in June 2023, the acquiror's securityholding percentage on a partially diluted basis has decreased from 50.5% to his securityholding percentage immediately prior to the Private Placement as a result of certain transactions and events, including the two following transactions which resulted in each case in a decrease in the acquiror's securityholding percentage by 2% or more since the prior event: (i) on July 31, 2024, the acquiror, disposed of 470,000 Common Shares held by 102042227 Saskatchewan Ltd. (' 102 Sask '), an entity controlled by the acquiror to in satisfaction of payments due in the aggregate amount of $432,400 (the ' July 2024 Event '); and (ii) on September 4, 2024,14,088 Warrants with an exercise price of $3.55 per Common Share previously issued to 102 Sask on March 4, 2022 expired unexercised (the ' September 2024 Event '). Immediately prior to the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 34,173,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 48.2% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.8% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 47.6% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.1% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror's securityholding percentage has decreased by 1.7% on an undiluted basis from the acquiror's securityholding percentage as at June 13, 2023 as disclosed in the 2023 EWR and has decreased by 2.3% on a partially diluted basis from the acquior's securityholding percentage as at June 13, 2023 (which was 50.5%). Immediately prior to the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 278,845 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on partially diluted basis. Following the September 2024 Event, the acquiror's securityholding percentage has decreased by 2.3% on an undiluted basis from the percentage held immediately following the July 2024 Event and has decreased by 2.2% on a partially diluted basis from the percentage held immediately following the July 2024 Event.
The Acquiror's transactions were made for investment purposes. The acquiror may, from time to time and at any time, acquire additional securities of ZYUS in the open market or otherwise, and may dispose of any or all of securities of ZYUS in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities of ZYUS, the whole depending on market conditions, the business and prospects of ZYUS and other relevant factors.
An early warning report will be filed by the Acquiror under applicable securities laws and will be available on ZYUS's SEDAR+ profile at www.sedarplus.ca.
For more information, please contact the Acquiror at 204-407 Downey Road, Saskatoon, SK S7N 4L8; telephone: (306) 242-2357
View source version on businesswire.com:https://www.businesswire.com/news/home/20250627943504/en/
(306) 242-2357
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: ZYUS Life Sciences Corporation
Copyright Business Wire 2025.
PUB: 06/27/2025 10:53 PM/DISC: 06/27/2025 10:53 PM
http://www.businesswire.com/news/home/20250627943504/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Jeff Bezos and Lauren Sánchez are one of the richest married couples. Here's how the ultrawealthy do prenups.
With Jeff Bezos and Lauren Sánchez now married, they're likely to have a complex prenup. Lawyers and wealth management experts outlined the prenup process for the superrich. Business control, property ownership, and trusts are just some of the questions prenups tackle. Hindsight is 20/20 — especially when hindsight is worth $38 billion. Amazon founder Jeff Bezos and MacKenzie Scott, his first wife, got married without a prenup (in 1993, before Bezos started Amazon). Scott received roughly $38 billion in Amazon shares in the settlement, making her one of the world's richest women. On Friday, Bezos got married again, this time to helicopter pilot and former journalist Lauren Sánchez. Experts in family law and wealth management told Business Insider that the couple is almost certain to have a complex prenup. Bezos is, after all, worth more than $200 billion today. A representative for Bezos didn't respond to a request for comment from BI about whether the couple has a prenup. Anne Paape, the managing director and head of wealth strategy at Cresset Capital, a multi-family office for entrepreneurs and multi-generational families of wealth, said prenups are generally becoming more common and are sometimes even mandated in family trusts for the ultrawealthy. Prenups begin with both people fully disclosing their financial assets and debts, she said. Besides family, they can also involve everyone from business partners and tax attorneys to luxury realtors and aviation experts who help appraise homes and private jets, said Brooke Summerhill, a divorce financial consultant who primarily works with ultra-high net worth clients. "It's not the clients making a lot of these decisions, it's their team helping them understand what those decisions are and making those decisions with them," she told BI. Paape doesn't know the details of Bezos' potential prenup but said his situation isn't entirely unique: Many superrich weddings mark second or third marriages for at least one spouse, often one whose assets have changed considerably since their first time tying the knot. "He will absolutely have protection against anything that he could," Summerhill said, adding that he likely won't let his pre-marriage assets co-mingle with Sánchez's assets. The more money you have, the more potential prenup headaches you'll have, especially when it comes to business interests and properties. Wealthy clients tend to have properties and business interests around the globe, making it harder to ensure compliance with divorce and death laws in various jurisdictions. Many entrepreneurs like Bezos are focused on insulating their businesses in the event of a divorce or death. Most don't want to risk giving an ex-partner enough stock to have a say in how the company runs, Paape told BI. "You could try to compensate for keeping that off the table," Paape said. "What else if you were to get divorced? What other resources could you provide to that person?" Clauses safeguarding the appreciation of assets during a marriage are also key for wealthy clients, Summerhill said. If the couple ever divorces, it's not unlikely that Sánchez would get a lump sum, Amazon shares, and some real estate, according to Summerhill and Raymond Hekmat, a family law attorney in Beverly Hills who primarily writes prenups. But a marriage can also end in death, and that's where a death clause can come in. As Summerhill put it, this "prevents the surviving spouse from claiming a bigger portion of that deceased person's separate property." A surviving spouse commonly receives a lump sum or life insurance payout upon their spouse's death, she said, but a last will and testament may take precedent over the prenup. Prenups for the ultrawealthy have repercussions beyond the couple, whether it's about who takes over the family empire or gets the keys to the Hamptons home. "There's more people that care about the resolution of that breakup, whether it's divorce or death," Paape said. "It's business partners, it's employees, it's charities you support, it's children and grandchildren." She said trusts "are a no-brainer " for children of the ultrarich and that many provisions deal with inherited property or business ownership. Bezos shares four children with Scott, and Sánchez has three kids. Hekmat said all the prenups he draws up have a confidentiality provision, and some can include social media restrictions. "In the event of a breakup, you can't disparage the other party or discuss the prenup in any way with the public, and there could be penalties involved," he said. Prenups can also include sunset clauses, which say that some provisions or even the full agreement expires after a certain period of time. Some people may choose to change certain provisions and become more generous after they've been with their spouse for a while, Paape said. Hekmat said that even with prenups, couples risk messy legal and financial fights down the line. Proclaimed love and devotion aside, he kept his advice for the Bezoses of the world simple. "My bottom line for billionaires is don't get married." Have a tip or a story to share about your own experiences with a prenup? Contact these reporters via email at atecotzky@ or sjackson@ or on Signal at alicetecotzky.05. Use a personal email address and a nonwork device; here's our guide to sharing information securely. Read the original article on Business Insider
Yahoo
18 minutes ago
- Yahoo
Is Danaher's M&A Premium Already Priced In?
Danaher Corporation (NYSE: DHR) is a global science and technology innovator focused on designing, manufacturing, and marketing professional, medical, industrial, and commercial products and services. Following the 2023 spin-off of its Environmental & Applied Solutions segment (now Veralto), Danaher has transformed into a pure-play life sciences and diagnostics company, operating through three primary segments: Biotechnology, Life Sciences, and Diagnostics. Warning! GuruFocus has detected 4 Warning Signs with DHR. Biotechnology (~30% of FY2024 revenue) includes Danaher's bioprocessing and genomic reagents businesses, led by brands like Cytiva and Pall, serving pharmaceutical and biotech companies in biologics production and Sciences (~25% of revenue) offers analytical instruments, microscopy, and lab automation tools used by academic institutions, research labs, and clinical diagnostics developers. Key platforms include Leica Microsystems, SCIEX, and Beckman Coulter Life (~45% of revenue) comprises molecular diagnostics, core laboratory diagnostics, and point-of-care testing systems. Notably, Cepheidone of Danaher's flagship brandsoffers rapid molecular diagnostic testing platforms, particularly for infectious diseases like COVID-19, influenza, and tuberculosis. Danaher reported a better-than-feared quarter, beating both top and bottom line estimates significantly and maintaining its annual guidance. In Q1 FY2025, the company's total sales declined by 1% YoY to $5,741 million from $5,796 million in the previous year's quarter. The decline was due to -1.5% impact from foreign exchange translation, which was partially offset by 0.5% growth through acquisitions and flat core revenue growth. The revenue from the Biotechnology segment grew by 6% YoY to $1,612 million, driven by an increase in core sales from high-growth markets due to a rise in demand. The Life Sciences segment saw a decline of 3.5% YoY to $1,680 million due to a decrease in core sales in the genomics consumables business. Revenue from the Diagnostics segment declined by 3% YoY to $2,449 million due to a decline in the sales of the molecular diagnostic business and lower sales in the China region. The adjusted operating profit declined by 50 bps YoY to 29.6% in the quarter due to product mix, administrative cost structure, currency exchange rates, and acquisition Corporation's Growth & Cash Flow Danaher is positioned as a leading provider of life sciences, diagnostic, and biotechnology equipment after spinning off its environmental business (Veralto) in late 2023. Management's guidance for FY2025 assumes relatively stable end-market demand for the rest of the year (similar to Q1 levels). Against this backdrop, I believe Danaher should grow modestly in 2025, reflecting both macro headwinds (tariffs, academic budget cuts) and continued strength in critical segments. I have mentioned the guidance provided by the management below, and my thesis that should help the company achieve it. For fiscal 2025, Danaher reaffirmed core revenue growth of roughly +3% year-over-year. This is consistent with management's view that market demand (globally) will be relatively consistent with Q1, despite tariffs and other pressures. Adjusted diluted EPS guidance was set at $7.60$7.75 (vs. $7.68 consensus). Notably, management raised its Bioprocessing (biotech) growth forecast to the high-single-digits for 2025 (from a prior 67% outlook). Bioprocessing is Danaher's fastest-growing segment. Robust demand for biologic drug development kits and reagents drove higher Q1 results and should continue to drive growth for the remainder of FY2025. Furthermore, the segment is emerging from the destocking cycle, which should help drive sales. In contrast, the Life Sciences segment forecast was trimmed to essentially flat growth, as funding uncertainties slowed academic and government sales (particularly in the U.S.), and China's medical equipment sector has experienced some softness. This should offset the healthy growth in the Bioprocessing segment. However, any rebound in global R&D spending (or continued Chinese stimulus) could surprise on the upside. The Diagnostics segment (especially Cepheid's molecular tests) is expected to see modest growth: Cepheid's respiratory test sales are forecast to reach around $1.7 billion for 2025, but production volume will return to a normal seasonal level after Q1. Overall, Danaher's portfolio remains tilted toward high-growth medical and diagnostics markets, which underpins its steady outlook despite industry headwinds. A key uncertainty is trade policy: Danaher estimates that current U.S. and European tariffs could add roughly $350 million in costs in 2025. However, the company has long worked to offset these costs via its Danaher Business System (DBS), regionalized manufacturing, and pricing strategies. The company should absorb much of the tariff impact through cost actions and supply-chain adjustments (e.g., surcharges or shifting production) rather than curtailing R&D or major initiatives. Because Danaher's products (lab instruments, diagnostics, and biotech consumables) are often mission-critical in healthcare, I believe its end markets will remain resilient even under tariff pressure. In short, tariffs represent a moderate headwind, but Danaher should largely neutralize the impact by expense reductions and operational flexibility. Margins in the upcoming quarters are expected to contract largely due to seasonality in Cepheid's respiratory testing business. Cepheid is one of Danaher's higher?margin units, and Q2 respiratory kit revenue is assumed to be only about $250 million (vs. ~$625 million in Q1). This sharp seasonal drop in high-margin sales, plus normal diagnostic restructuring costs (e.g., the management of China's reimbursement changes), drives the lower quarter?on?quarter profit margin. In sum, I believe the company's margins should continue to decline and improve in the back half of 2025. As a company built on decades of disciplined capital deployment, Danaher's ability to acquire and successfully integrate businesses has been one of its defining competitive advantages. Flagship acquisitions like Cepheid and Pall have meaningfully strengthened Danaher's diagnostics and bioprocessing platforms, but they also introduce inherent integration risks. These include short-term pressures on margins, incremental R&D and SG&A costs, and the complexities of aligning acquired operations with Danaher's operating structure. While such challenges are typical of any acquisitive strategy, Danaher's track record sets it apart. Over the past 30 years, the company has repeatedly demonstrated its ability to extract synergies, improve productivity, and scale acquisitions effectively, largely driven by the Danaher Business System (DBS). This system institutionalizes continuous improvement, cost efficiency, and cultural integration across its portfolio. Though former CEO Larry Culp played a pivotal role in establishing this M&A discipline, the company's current leadership remains strongly committed to DBS principles, which continue to guide its post-acquisition integration efforts. Moreover, Danaher doesn't pursue acquisitions purely for scale; it focuses on high-quality, strategic assets that complement existing platforms and offer long-term value creation. While integration may temporarily weigh on profitability, especially in the form of restructuring expenses, near-term dilution, or elevated investments in innovation, these are often calculated trade-offs for future operating leverage and market expansion. In essence, what might be viewed as a risk is also one of Danaher's greatest strengths; its consistent ability to turn acquired assets into high-margin, growth-focused businesses that reinforce its leadership in life sciences and diagnostics. As of March 31, 2025, investor activity around Danaher reflected a balanced mix of strategic repositioning and continued confidence in the company's long-term potential. Notably, renowned value investors like Joel Greenblatt (Trades, Portfolio) (+29.03%), Wallace Weitz (Trades, Portfolio) (+23.17%), and Arnold Van Den Berg (Trades, Portfolio) (+14.62%) significantly increased their holdings, signaling optimism about Danaher's focused life sciences and diagnostics trajectory. Ken Fisher (Trades, Portfolio) also added modestly to his position (+1.23%), reinforcing steady institutional support. While some investors like Jefferies Group (Trades, Portfolio), Mario Gabelli (Trades, Portfolio), and George Soros (Trades, Portfolio) trimmed their stakes. Danaher is currently trading at a forward P/E of 25.5x and 22.9x on FY2025 and FY2026 estimated EPS of $7.70 and $8.57, respectively, which is below its five-year average forward P/E of 29.9x. On an EV/EBITDA basis, Danaher trades at approximately 18xhigher than peers such as Thermo Fisher Scientific (P/E ~15x, EV/EBITDA ~13x) and Agilent Technologies (P/E ~21x, EV/EBITDA ~15x). While Danaher's valuation premium may appear elevated relative to peers, it reflects the company's consistent execution, higher exposure to recurring revenue from consumables, and strong margin profile. The market seems cautiously optimistic, pricing in steady growth expectations. For FY2025, Danaher's outlook implies stable and controlled expansion, led primarily by strong bioprocessing demand. Although adjusted operating margins are expected to decline in Q2 due to seasonal normalization in the high-margin Cepheid business, a recovery is anticipated in the latter half of the year. Danaher's long-standing execution discipline, anchored by the Danaher Business System (DBS), equips it to offset macro pressures through operational efficiency and agile supply chain management. With a focused portfolio in mission-critical life sciences and diagnostics, Danaher remains well-positioned to deliver modest yet resilient growth in 2025, supported by strategic capital deployment and a strong competitive moat. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Coinbase Outpaces S&P 500 With 43% June Rise as Stablecoin Narrative Grows: CNBC
Shares of Nasdaq-listed cryptocurrency exchange Coinbase (COIN) rose 43% this month, making the firm the top performer in the S&P 500 since it joined the index at the end of last month. June's run is already the stock's best since November and caps three straight monthly gains. Coinbase's shares reached their highest level since their public debut. COIN hit a $382 high this week before enduring a slight correction, ending the week at $353 and seeing a slight 0.7% drop in after-hours trading to $351. The wider S&P 500 index rose roughly 5% in June as geopolitical tensions eased. Washington's progress on the GENIUS Act, Congress's first rulebook for dollar-pegged stablecoins, helped shift investor focus from trading fees to stablecoin revenue. The bill brightened the outlook for Circle, whose shares hit a record high and saw its market cap near that of Coinbase this week. Coinbase keeps all yield on USDC balances held on its platform and nearly half of other USDC income, equal to about 99 percent of Circle's revenue, giving shareholders indirect exposure at no added cost, CNBC reported Friday, citing analysts including Citizens' head of financial technology research Devin Ryan. Trading, however, remains subdued. Average daily volume on Coinbase has drifted lower since April. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
